Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9429192 | Neuroscience Letters | 2005 | 5 Pages |
Abstract
NGP1-01, a member of the pentacycloundecylamine cage compound family, was recently shown to exhibit both NMDA receptor channel blocking and L-type calcium channel antagonism activity. In the present study, focal ischemia was induced in mice by permanent middle cerebral artery occlusion (MCAO) to test for potential neuroprotective properties of the compound. In female CD-1 mice injected 30Â min before MCAO, NGP1-01 (20Â mg/kg) reduced infarct area by 42.6% (PÂ <Â 0.05) compared to vehicle-treated controls as visualized by 2,3,5-triphenyltetrazolium chloride (TTC) staining. Concomitantly, NGP1-01 reduced brain swelling by 78.3% (PÂ <Â 0.001), compared to vehicle (DMSO) treated controls. These data identify NGP1-01 and related compounds as potential lead structures to develop neuroprotective compounds based on a dual mechanism of action.
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
Alexander Mdzinarishvili, Werner J. Geldenhuys, Thomas J. Abbruscato, Ulrich Bickel, Jochen Klein, Cornelis J. Van der Schyf,